Transradial Technologies Inc

Transradial Technologies Inc. is a medical device company focused on developing a novel, minimally invasive transradial vascular closure device. The device is designed to offer a “fast, safe, and easy-to-use” closure solution for radial artery punctures created during a full range of interventional procedures including cardiac catheterization, percutaneous coronary revascularization, and peripheral angiography/revascularization. Suction Activated Patent Hemostasis) – Designed to address the growing market of procedures performed using radial artery access, the SĀPH device uniquely closes the arterial puncture by expanding the artery to create compression with the artery puncture site and the surrounding tissue rather than the traditional method of compressing the artery with a tourniquet around the wrist. The SĀPH device achieves a lower rate of radial artery occlusion, a more comfortable patient experience, and importantly, reduces the workload for recovery staff, (i.e. no intermittent patient monitoring is necessary). First in man testing (17 patients) has been successfully completed. This technology is also well suited to transpedal and distal radial arterial access and potentially femoral venous procedures. Competition The current standard of care, conventional compression, utilizes a tourniquet-band and inflatable bladder which compresses and flattens the wrist and artery, restricting blood flow, and creating significant discomfort for the patient. Terumo Corporation currently holds a predominant market share (>70%) in this conventional compression category. Many large companies, such as Boston Scientific, Medtronic, Abbott, Merit Medical and Teleflex have significant presence in the hospital where the procedures occur and have little or no radial access vascular closure sales.